Stemline Therapeutics closes $92 million public offering of common stock
Stemline Therapeutics announced the closing of a previously announced underwritten public offering of 10,222,222 shares of its common stock, which included the exercise in full of the option to purchase 1,333,333 additional shares, at a price of $9.00 per share. January 18, 2019